Literature DB >> 28975592

Authors' Reply to Yilmaz and Türk: "Targeting the PGD2/CRTH2/DP1 Signaling Pathway in Asthma and Allergic Disease: Current Status and Future Perspectives".

Maciej Kupczyk1,2, Piotr Kuna3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28975592     DOI： 10.1007/s40265-017-0822-1

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  5 in total

1.  Aspirin-Exacerbated Respiratory Disease--New Prime Suspects.

Authors:  Tanya M Laidlaw; Joshua A Boyce
Journal:  N Engl J Med       Date:  2016-02-04       Impact factor: 91.245

2.  Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma.

Authors:  Philippe Gevaert; Lien Calus; Thibaut Van Zele; Katrien Blomme; Natalie De Ruyck; Wouter Bauters; Peter Hellings; Guy Brusselle; Dirk De Bacquer; Paul van Cauwenberge; Claus Bachert
Journal:  J Allergy Clin Immunol       Date:  2012-09-27       Impact factor: 10.793

3.  Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial.

Authors:  Sven-Erik Dahlén; Kerstin Malmström; Ewa Nizankowska; Barbro Dahlén; Piotr Kuna; Marek Kowalski; William R Lumry; César Picado; Donald D Stevenson; Jean Bousquet; Romain Pauwels; Stephen T Holgate; Aditi Shahane; Ji Zhang; Theodore F Reiss; Andrew Szczeklik
Journal:  Am J Respir Crit Care Med       Date:  2002-01-01       Impact factor: 21.405

4.  Aspirin intolerance and allergy to house dust mites: important factors associated with development of severe asthma.

Authors:  Maciej Kupczyk; Izabela Kupryś; Paweł Górski; Piotr Kuna
Journal:  Ann Allergy Asthma Immunol       Date:  2004-04       Impact factor: 6.347

Review 5.  Targeting the PGD2/CRTH2/DP1 Signaling Pathway in Asthma and Allergic Disease: Current Status and Future Perspectives.

Authors:  Maciej Kupczyk; Piotr Kuna
Journal:  Drugs       Date:  2017-08       Impact factor: 9.546
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.